<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="Symbol" color="#000000"/>
	<fontspec id="font6" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font7" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
<text top="42" left="57" width="184" height="7" font="font0" id="p1_t1" reading_order_no="1" segment_no="0" tag_type="title">Breast Cancer Research Vol 7 No 6    Dalenc et al.<b>Breast Cancer Research</b></text>
<text top="735" left="18" width="23" height="8" font="font3" id="p1_t2" reading_order_no="0" segment_no="14" tag_type="text">R1160</text>
<text top="85" left="57" width="240" height="9" font="font4" id="p1_t3" reading_order_no="2" segment_no="1" tag_type="text">cancer, combination therapies using two or more antitumour<i>et al.</i></text>
<text top="97" left="57" width="240" height="9" font="font4" id="p1_t4" reading_order_no="3" segment_no="1" tag_type="text">drugs with differing mechanisms of action have generally</text>
<text top="109" left="57" width="240" height="9" font="font4" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">proved more effective than single-drug therapies. In this basis,</text>
<text top="120" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="5" segment_no="1" tag_type="text">combinations of FTIs with a variety of commonly used antican-</text>
<text top="132" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="6" segment_no="1" tag_type="text">cer agents have been tested on human tumours [1]. The FTI</text>
<text top="144" left="57" width="241" height="9" font="font4" id="p1_t8" reading_order_no="7" segment_no="1" tag_type="text">R115,777 represents one of the first-in-class inhibitors to</text>
<text top="156" left="57" width="240" height="9" font="font4" id="p1_t9" reading_order_no="8" segment_no="1" tag_type="text">enter the clinic [2]. Clinical trials have shown that this com-<a href="">[1]. </a>The FTI</text>
<text top="167" left="57" width="240" height="9" font="font4" id="p1_t10" reading_order_no="9" segment_no="1" tag_type="text">pound has an acceptable safety profile, allowing the adminis-</text>
<text top="179" left="57" width="240" height="9" font="font4" id="p1_t11" reading_order_no="10" segment_no="1" tag_type="text">tration of biologically active doses. Phase II clinical trials in<a href="">ic [2]. </a>Clinical trials have shown that this com-</text>
<text top="191" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="11" segment_no="1" tag_type="text">patients with metastatic breast carcinoma have shown that</text>
<text top="203" left="57" width="241" height="9" font="font4" id="p1_t13" reading_order_no="12" segment_no="1" tag_type="text">R115,777 has reproducible single-agent activity [3]. In this</text>
<text top="214" left="57" width="240" height="9" font="font4" id="p1_t14" reading_order_no="13" segment_no="1" tag_type="text">present study, the activity of combined treatment with Tam and</text>
<text top="226" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="14" segment_no="1" tag_type="text">R115,777 was investigated using a mammary cancer cell line<a href="">single-agent activity [3]. In this</a></text>
<text top="238" left="57" width="240" height="9" font="font4" id="p1_t16" reading_order_no="15" segment_no="1" tag_type="text">(MCF-7), and the results are compared with those from our</text>
<text top="250" left="57" width="240" height="9" font="font4" id="p1_t17" reading_order_no="16" segment_no="1" tag_type="text">previous studies using FTI-277 (an experimental FTI not in clin-</text>
<text top="261" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="17" segment_no="1" tag_type="text">ical usage) to evaluate the potential value of this combined</text>
<text top="273" left="57" width="202" height="9" font="font4" id="p1_t19" reading_order_no="18" segment_no="1" tag_type="text">therapy in the treatment of advanced breast cancer.</text>
<text top="297" left="57" width="240" height="9" font="font4" id="p1_t20" reading_order_no="19" segment_no="6" tag_type="text">The antitumour effect of Tam is believed to be due to a combi-</text>
<text top="308" left="57" width="240" height="9" font="font4" id="p1_t21" reading_order_no="20" segment_no="6" tag_type="text">nation of hormone receptor dependent (estrogen receptor</text>
<text top="318" left="57" width="240" height="12" font="font4" id="p1_t22" reading_order_no="21" segment_no="6" tag_type="text">(ER)-mediated with two receptor subtypes, ER α and ER β ) and</text>
<text top="332" left="57" width="240" height="9" font="font4" id="p1_t23" reading_order_no="22" segment_no="6" tag_type="text">independent (non-ER-mediated) mechanisms [4]. The signal-</text>
<text top="344" left="57" width="240" height="9" font="font4" id="p1_t24" reading_order_no="23" segment_no="6" tag_type="text">ling proteins in the non-ER-mediated pathways [5] include</text>
<text top="355" left="57" width="240" height="9" font="font4" id="p1_t25" reading_order_no="24" segment_no="6" tag_type="text">interactions with microsomal anti-estrogen-binding sites</text>
<text top="367" left="57" width="240" height="9" font="font4" id="p1_t26" reading_order_no="25" segment_no="6" tag_type="text">(AEBS) that are high affinity binding sites for Tam [6,7]. AEBS</text>
<text top="377" left="57" width="241" height="12" font="font4" id="p1_t27" reading_order_no="26" segment_no="6" tag_type="text">are different from ERs because they have no affinity for 17 β -</text>
<text top="391" left="57" width="240" height="9" font="font4" id="p1_t28" reading_order_no="27" segment_no="6" tag_type="text">estradiol or steroidal anti-estrogens, and we recently reported</text>
<text top="402" left="57" width="240" height="9" font="font4" id="p1_t29" reading_order_no="28" segment_no="6" tag_type="text">that these sites consist of several proteins involved in choles-<a href="">sms [4]. Th</a>e signal-</text>
<text top="414" left="57" width="240" height="9" font="font4" id="p1_t30" reading_order_no="29" segment_no="6" tag_type="text">terol metabolism [8]. Previous reports have suggested that<a href="">[5] i</a>nclude</text>
<text top="426" left="57" width="240" height="9" font="font4" id="p1_t31" reading_order_no="30" segment_no="6" tag_type="text">Tam inhibits MCF-7 cell proliferation [9] by binding to both</text>
<text top="438" left="57" width="240" height="9" font="font4" id="p1_t32" reading_order_no="31" segment_no="6" tag_type="text">ERs and AEBS [7,10] and can induce apoptotic cell death,<a href="">sites for Tam [6,7]</a>. AEBS</text>
<text top="449" left="57" width="133" height="9" font="font4" id="p1_t33" reading_order_no="32" segment_no="6" tag_type="text">both in vitro [11] and in vivo [12].</text>
<text top="473" left="57" width="240" height="9" font="font4" id="p1_t34" reading_order_no="33" segment_no="9" tag_type="text">In parallel, FTIs inhibit the growth of a broad variety of human</text>
<text top="485" left="57" width="241" height="9" font="font4" id="p1_t35" reading_order_no="34" segment_no="9" tag_type="text">tumour cells in vitro and studies to date have not identified any</text>
<text top="496" left="57" width="240" height="9" font="font4" id="p1_t36" reading_order_no="35" segment_no="9" tag_type="text">cellular characteristics that predict the antitumour efficacy of</text>
<text top="508" left="57" width="240" height="9" font="font4" id="p1_t37" reading_order_no="36" segment_no="9" tag_type="text">this class of agent. In vitro , however, FTI treatment of tumour</text>
<text top="520" left="57" width="240" height="9" font="font4" id="p1_t38" reading_order_no="37" segment_no="9" tag_type="text">cells has been associated with activation of apoptotic path-<a href="">terol metabolism [8]. P</a>revious reports have suggested that</text>
<text top="532" left="57" width="41" height="9" font="font4" id="p1_t39" reading_order_no="38" segment_no="9" tag_type="text">ways [13].<a href="">proliferation [9] </a>by binding to both</text>
<text top="555" left="57" width="240" height="9" font="font4" id="p1_t40" reading_order_no="39" segment_no="12" tag_type="text">We have previously shown the involvement of pocket proteins<a href="">7,10] and </a>can induce apoptotic cell death,</text>
<text top="567" left="57" width="240" height="9" font="font4" id="p1_t41" reading_order_no="40" segment_no="12" tag_type="text">[14] and genomic ER effects [15] in the additive efficacy of a</text>
<text top="579" left="57" width="240" height="9" font="font4" id="p1_t42" reading_order_no="41" segment_no="12" tag_type="text">combination of Tam and FTI277. To dissect out that portion of<i>in vitro </i></text>
<text top="590" left="57" width="240" height="9" font="font4" id="p1_t43" reading_order_no="42" segment_no="12" tag_type="text">the Tam effect associated with the 'AEBS pathway', we com-<a href="">[11] and </a></text>
<text top="602" left="57" width="240" height="9" font="font4" id="p1_t44" reading_order_no="43" segment_no="12" tag_type="text">pare here the effects of combining R115,777 with a selective<i>in vivo </i></text>
<text top="614" left="57" width="240" height="9" font="font4" id="p1_t45" reading_order_no="44" segment_no="12" tag_type="text">AEBS ligand (N-pyrrolidine(-phenylmethyl-phenoxy)-ethan-<a href="">[12].</a></text>
<text top="626" left="57" width="240" height="9" font="font4" id="p1_t46" reading_order_no="45" segment_no="12" tag_type="text">amine-HCl (PBPE)) [10] or with a selective estrogen receptor</text>
<text top="637" left="57" width="240" height="9" font="font4" id="p1_t47" reading_order_no="46" segment_no="12" tag_type="text">ligand (ICI182,780) on MCF-7 cell proliferation. The effects of</text>
<text top="649" left="57" width="240" height="9" font="font4" id="p1_t48" reading_order_no="47" segment_no="12" tag_type="text">such treatments on the induction of cellular apoptosis have<i>in vitro </i></text>
<text top="661" left="57" width="240" height="9" font="font4" id="p1_t49" reading_order_no="48" segment_no="12" tag_type="text">been evaluated by monitoring cell cycle alterations and cas-</text>
<text top="673" left="57" width="240" height="9" font="font4" id="p1_t50" reading_order_no="49" segment_no="12" tag_type="text">pase involvement. The contribution of ERs to apoptosis induc-</text>
<text top="684" left="57" width="240" height="9" font="font4" id="p1_t51" reading_order_no="50" segment_no="12" tag_type="text">tion has also been determined by comparing the effects of</text>
<text top="696" left="57" width="240" height="9" font="font4" id="p1_t52" reading_order_no="51" segment_no="12" tag_type="text">combined treatments with either the pure anti-estrogen<i>In vitro</i></text>
<text top="708" left="57" width="189" height="9" font="font4" id="p1_t53" reading_order_no="52" segment_no="12" tag_type="text">ICI182,780 or the AEBS selective ligand PBPE.</text>
<text top="85" left="315" width="121" height="10" font="font7" id="p1_t54" reading_order_no="53" segment_no="2" tag_type="title">Materials and methods</text>
<text top="97" left="315" width="40" height="8" font="font8" id="p1_t55" reading_order_no="54" segment_no="3" tag_type="title">Cell lines<a href=""> [13].</a></text>
<text top="109" left="315" width="240" height="9" font="font4" id="p1_t56" reading_order_no="55" segment_no="4" tag_type="text">The human adenocarcinoma breast cell line MCF-7 was</text>
<text top="120" left="315" width="240" height="9" font="font4" id="p1_t57" reading_order_no="56" segment_no="4" tag_type="text">obtained from the American Tissue Culture Collection (Manas-<a href="">[14] and gen</a>o<a href="">mic ER effects [15] in th</a>e additive efficacy of a</text>
<text top="132" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="57" segment_no="4" tag_type="text">sas, VA, USA). MCF-7 cells were grown routinely in RPMI</text>
<text top="144" left="315" width="240" height="9" font="font4" id="p1_t59" reading_order_no="58" segment_no="4" tag_type="text">1640 medium supplemented with 5% fetal bovine serum</text>
<text top="156" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="59" segment_no="4" tag_type="text">(Gibco BRL, Life Technologies, Cergy Pontoise, France) and</text>
<text top="167" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="60" segment_no="4" tag_type="text">2 mM L-glutamine. The cells were incubated at 37°C in a</text>
<text top="179" left="315" width="118" height="10" font="font4" id="p1_t62" reading_order_no="61" segment_no="4" tag_type="text">humidified 5% CO 2 incubator.<a href="">) [10] or wi</a>th a selective estrogen receptor</text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t63" reading_order_no="62" segment_no="5" tag_type="text">For all experiments, the cells were treated with R115,777</text>
<text top="214" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="63" segment_no="5" tag_type="text">(Janssen Research Foundation, Janssen Pharmaceutica, L.P.,</text>
<text top="226" left="315" width="240" height="9" font="font4" id="p1_t65" reading_order_no="64" segment_no="5" tag_type="text">Titusville, NJ 08560, USA), Tam (Sigma-Aldrich S.a.r.l. St</text>
<text top="238" left="315" width="240" height="9" font="font4" id="p1_t66" reading_order_no="65" segment_no="5" tag_type="text">Quentin Fallavier, France), ICI182,780 (Tocris Bioscience,</text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t67" reading_order_no="66" segment_no="5" tag_type="text">Ellisville, Missouri 63021 USA), PBPE (synthesized in our lab-</text>
<text top="261" left="315" width="240" height="9" font="font4" id="p1_t68" reading_order_no="67" segment_no="5" tag_type="text">oratory) [16] or vehicle, and the medium was changed every 2</text>
<text top="273" left="315" width="241" height="9" font="font4" id="p1_t69" reading_order_no="68" segment_no="5" tag_type="text">days. R115,777, Tam, ICI182,780 and PBPE were all dis-</text>
<text top="284" left="315" width="241" height="10" font="font4" id="p1_t70" reading_order_no="69" segment_no="5" tag_type="text">solved in ethanol and then diluted 10 3 -fold directly into the cul-<b>Materials and methods</b></text>
<text top="297" left="315" width="51" height="9" font="font4" id="p1_t71" reading_order_no="70" segment_no="5" tag_type="text">ture medium.<b>Cell lines</b></text>
<text top="320" left="315" width="183" height="8" font="font8" id="p1_t72" reading_order_no="71" segment_no="7" tag_type="title">Sulphorhodamine B assay for proliferation</text>
<text top="332" left="315" width="240" height="9" font="font4" id="p1_t73" reading_order_no="72" segment_no="8" tag_type="text">The quantitative sulphorhodamine B (SRB) colorimetric assay</text>
<text top="344" left="315" width="240" height="9" font="font4" id="p1_t74" reading_order_no="73" segment_no="8" tag_type="text">[17] was used to determine the growth inhibitory effect of</text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t75" reading_order_no="74" segment_no="8" tag_type="text">drugs on MCF-7 cells. Cells were seeded at 3,500 per well in</text>
<text top="367" left="315" width="240" height="9" font="font4" id="p1_t76" reading_order_no="75" segment_no="8" tag_type="text">96-well plates and grown for 24 h. The cells were then treated</text>
<text top="379" left="315" width="240" height="9" font="font4" id="p1_t77" reading_order_no="76" segment_no="8" tag_type="text">with increasing concentrations of compounds and grown for a</text>
<text top="391" left="315" width="240" height="9" font="font4" id="p1_t78" reading_order_no="77" segment_no="8" tag_type="text">further 5 days. The medium was changed after 2 days. At the</text>
<text top="402" left="315" width="240" height="9" font="font4" id="p1_t79" reading_order_no="78" segment_no="8" tag_type="text">end of the incubation, cells were fixed with 50% trichloracetic</text>
<text top="414" left="315" width="241" height="9" font="font4" id="p1_t80" reading_order_no="79" segment_no="8" tag_type="text">acid (1 h at 4°C), stained for 30 minutes at room temperature</text>
<text top="424" left="315" width="240" height="12" font="font4" id="p1_t81" reading_order_no="80" segment_no="8" tag_type="text">with 50 µ l of a 0.4% w/v SRB solution (Sigma) in 1% acetic</text>
<text top="438" left="315" width="241" height="9" font="font4" id="p1_t82" reading_order_no="81" segment_no="8" tag_type="text">acid. SRB was then removed and cells were quickly rinsed</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t83" reading_order_no="82" segment_no="8" tag_type="text">four times with 1% acetic acid. After air-drying, protein-bound</text>
<text top="459" left="315" width="241" height="12" font="font4" id="p1_t84" reading_order_no="83" segment_no="8" tag_type="text">dye was dissolved in 150 µ l of 10 mM unbuffered Tris base</text>
<text top="473" left="315" width="240" height="9" font="font4" id="p1_t85" reading_order_no="84" segment_no="8" tag_type="text">(pH 10.5) for 5 minutes on a gyratory shaker. The pink SRB</text>
<text top="485" left="315" width="241" height="9" font="font4" id="p1_t86" reading_order_no="85" segment_no="8" tag_type="text">was quantified by measuring the optical density at 540 nm. For<a href=""> [16] </a>or vehicle, and the medium was changed every 2</text>
<text top="496" left="315" width="240" height="9" font="font4" id="p1_t87" reading_order_no="86" segment_no="8" tag_type="text">each condition, average cell density and the standard devia-</text>
<text top="508" left="315" width="181" height="9" font="font4" id="p1_t88" reading_order_no="87" segment_no="8" tag_type="text">tion were calculated from the data of six wells.</text>
<text top="532" left="315" width="92" height="8" font="font8" id="p1_t89" reading_order_no="88" segment_no="10" tag_type="title">Isobologram analysis</text>
<text top="543" left="315" width="240" height="9" font="font4" id="p1_t90" reading_order_no="89" segment_no="11" tag_type="text">Dose response interactions between the following combina-</text>
<text top="555" left="315" width="240" height="9" font="font4" id="p1_t91" reading_order_no="90" segment_no="11" tag_type="text">tions: R115,777-Tam, R115,777-ICI182,780, R115,777-</text>
<text top="567" left="315" width="240" height="10" font="font4" id="p1_t92" reading_order_no="91" segment_no="11" tag_type="text">PBPE at the IC 50 (inhibitory concentration 50%) point were<b>Sulphorhodamine B assay for proliferation</b></text>
<text top="579" left="315" width="240" height="9" font="font4" id="p1_t93" reading_order_no="92" segment_no="11" tag_type="text">evaluated by the isobologram method of Steel and Peckham</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t94" reading_order_no="93" segment_no="11" tag_type="text">[18]. When the data points of the drug combination fall within<a href="">[17]</a> was used to determine the growth inhibitory effect of</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t95" reading_order_no="94" segment_no="11" tag_type="text">the area surrounded by two lines (envelope of additivity), the</text>
<text top="614" left="315" width="240" height="9" font="font4" id="p1_t96" reading_order_no="95" segment_no="11" tag_type="text">combination is regarded as additive. When the data points of</text>
<text top="626" left="315" width="240" height="9" font="font4" id="p1_t97" reading_order_no="96" segment_no="11" tag_type="text">the drug combination fall to the left of the envelope (i.e., the</text>
<text top="637" left="315" width="240" height="9" font="font4" id="p1_t98" reading_order_no="97" segment_no="11" tag_type="text">combined effect is caused by lower doses of the two agents</text>
<text top="649" left="315" width="240" height="9" font="font4" id="p1_t99" reading_order_no="98" segment_no="11" tag_type="text">than predicted), the combination is regarded as having a</text>
<text top="661" left="315" width="240" height="9" font="font4" id="p1_t100" reading_order_no="99" segment_no="11" tag_type="text">supra-additive effect (synergism). Finally, when the data points</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t101" reading_order_no="100" segment_no="11" tag_type="text">fall to the right of the envelope, the combination is regarded as</text>
<text top="684" left="315" width="101" height="9" font="font4" id="p1_t102" reading_order_no="101" segment_no="11" tag_type="text">having a protective effect.</text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t103" reading_order_no="102" segment_no="13" tag_type="text">To determine the envelope of additivity, the two dose-</text>
<text top="720" left="315" width="241" height="9" font="font4" id="p1_t104" reading_order_no="103" segment_no="13" tag_type="text">response curves of R115,777 with either Tam, ICI182,780, or</text>
</page>
</pdf2xml>
